Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Physiol Rep ; 10(3): e15191, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35146951

RESUMO

The gut microbiota affects the host's metabolic phenotype, impacting health and disease. The gut-brain axis unites the intestine with the centers of hunger and satiety, affecting the eating behavior. Deregulation of this axis can lead to obesity onset. Litter size reduction is a well-studied model for infant obesity because it causes overnutrition and programs for obesity. We hypothesize that animals raised in small litters (SL) have altered circuitry between the intestine and brain, causing hyperphagia. We investigated vagus nerve activity, the expression of c-Fos, brain-derived neurotrophic factor (BDNF), gastrointestinal (GI) hormone receptors, and content of bacterial phyla and short-chain fatty acids (SCFAs) in the feces of adult male and female Wistar rats overfed during lactation. On the 3rd day after birth, litter size was reduced to 3 pups/litter (SL males or SL females) until weaning. Controls had normal litter size (10 pups/litter: 5 males and 5 females). The rats were killed at 5 months of age. The male and female offspring were analyzed separately. The SL group of both sexes showed higher food consumption and body adiposity than the respective controls. SL animals presented dysbiosis (increased Firmicutes, decreased Bacteroidetes) and had increased vagus nerve activity. Only the SL males had decreased hypothalamic GLP-1 receptor expression, while only the SL females had lower acetate and propionate in the feces and higher CCK receptor expression in the hypothalamus. Thus, overfeeding during lactation differentially changes the gut-brain axis, contributing to hyperphagia of the offspring of both sexes.


Assuntos
Eixo Encéfalo-Intestino , Hiperfagia/microbiologia , Tamanho da Ninhada de Vivíparos , Adiposidade , Animais , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Feminino , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Hiperfagia/metabolismo , Hiperfagia/fisiopatologia , Hipotálamo/metabolismo , Hipotálamo/fisiologia , Masculino , Proteínas Proto-Oncogênicas c-fos/metabolismo , Ratos , Ratos Wistar , Receptores da Colecistocinina/metabolismo , Nervo Vago/metabolismo , Nervo Vago/fisiologia
2.
Obes Facts ; 11(6): 440-453, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30537704

RESUMO

OBJECTIVE: This study evaluated the effect of a protein, the isolated Trypsin Inhibitor (TTI) from Tamarindus indica L. seed, as a CCK secretagogue and its action upon food intake and leptin in obese Wistar rats. METHODS: Three groups of obese rats were fed 10 days one of the following diets: Standard diet (Labina®) + water; High Glycemic Index and Load (HGLI) diet + water or HGLI diet + TTI. Lean animals were fed the standard diet for the 10 days. Food intake, zoometric measurements, plasma CCK, plasma leptin, relative mRNA expression of intestinal CCK-related genes, and expression of the ob gene in subcutaneous adipose tissue were assessed. RESULTS: TTI decreased food intake but did not increase plasma CCK in obese animals. On the other hand, TTI treatment decreased CCK-1R gene expression in obese animals compared with the obese group with no treatment (p = 0.027). Obese animals treated with TTI presented lower plasma leptin than the non-treated obese animals. CONCLUSION: We suggest that TTI by decreasing plasma leptin may improve CCK action, regardless of its increase in plasma from obese rats, since food intake was lowest.


Assuntos
Depressores do Apetite/farmacologia , Ingestão de Alimentos/efeitos dos fármacos , Leptina/sangue , Obesidade , Proteínas de Vegetais Comestíveis/farmacologia , Receptores da Colecistocinina/genética , Tamarindus/química , Animais , Depressores do Apetite/isolamento & purificação , Depressores do Apetite/uso terapêutico , Regulação para Baixo/efeitos dos fármacos , Expressão Gênica/efeitos dos fármacos , Masculino , Obesidade/sangue , Obesidade/tratamento farmacológico , Obesidade/genética , Proteínas de Vegetais Comestíveis/isolamento & purificação , Ratos , Ratos Wistar , Receptores da Colecistocinina/metabolismo , Resposta de Saciedade/efeitos dos fármacos , Sementes/química
3.
J Mol Neurosci ; 18(1-2): 97-104, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-11931355

RESUMO

Blockade of cholecystokinin (CCK) receptors potentiates the morphine-induced disruption of maternal behavior. The present study was undertaken to determine whether treatment with lorglumide, a CCK1 antagonist during late pregnancy and early lactation can influence the maternal behavior during lactation. A possible influence of this treatment on general activity was also assessed. Twenty-seven female Wistar rats were pretreated with lorglumide (1.0mg/kg/day; sc) or saline for seven days, starting on the 17th d of pregnancy. After the withdrawal of this treatment, animals were acutely challenged with saline on day 5 and with morphine sulfate (3.0mg/kg; sc) on days 6,10, and 17 of lactation. Groups were pretreated with saline and challenged with saline (group SS) and morphine (group SM), pretreated with lorglumide and challenged with saline (group LS) and morphine (group LM). Animals were also tested for general activity on days 25 and 33 postpartum after an acute challenge with saline and morphine, respectively. Maternal behavior testing began 30 min after the acute injections at which time pups were placed throughout each mother's cage. Latencies for pup retrieval, grouping, crouching and for full maternal behavior responses were scored. Lorglumide pretreatment inhibited maternal behavior of LS vs SS group and potentiated the morphine-induced disruption of this behavior in all days of test (LM vs SM group). No significant differences were found in general activity on days 25 and 33 postpartum. These data suggest that blockade of CCK1 receptors during puerperal period has long-term implications for maternal behavior.


Assuntos
Encéfalo/efeitos dos fármacos , Colecistocinina/metabolismo , Antagonistas de Hormônios/farmacologia , Lactação/efeitos dos fármacos , Comportamento Materno/efeitos dos fármacos , Morfina/farmacologia , Proglumida/análogos & derivados , Proglumida/farmacologia , Receptores da Colecistocinina/antagonistas & inibidores , Animais , Peso Corporal/efeitos dos fármacos , Peso Corporal/fisiologia , Encéfalo/metabolismo , Interações Medicamentosas/fisiologia , Feminino , Lactação/fisiologia , Masculino , Comportamento Materno/fisiologia , Atividade Motora/efeitos dos fármacos , Atividade Motora/fisiologia , Gravidez , Ratos , Ratos Wistar , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/fisiologia , Receptores da Colecistocinina/metabolismo
4.
Peptides ; 22(8): 1291-8, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11457523

RESUMO

Stereotyped behavior can be induced by the dopamine agonist apomorphine or by the releasing agent amphetamine. Cholecystokinin influence on dopamine-mediated behaviors has been extensively studied but a real controversy remains. Our purpose was to further characterize the dopamine-cholecystokinin interaction in apomorphine- and amphetamine-induced stereotyped behavior using sulphated cholecystokinin octapeptide (CCK8) and cholecystokinin tetrapeptide (CCK4) treatments. The results showed that CCK8 decreases apomorphine-induced stereotyped behavior and CCK4 has no effect. CCK4 and CCK8 increased the amphetamine-induced stereotyped behavior; CCK4 was more effective. The results confirm the opposite modulation of apomorphine or amphetamine-induced stereotyped behavior by CCK. These data suggest that this modulation is mediated by both CCK receptors on apomorphine-induced and only by CCK(2) receptors on amphetamine-induced stereotyped behavior.


Assuntos
Anfetaminas/farmacologia , Apomorfina/farmacologia , Colecistocinina/farmacologia , Agonistas de Dopamina/farmacologia , Dopamina/metabolismo , Interações Medicamentosas , Animais , Masculino , Ratos , Ratos Wistar , Receptores da Colecistocinina/metabolismo , Sincalida/farmacologia , Sinapses/efeitos dos fármacos , Tetragastrina/farmacologia , Fatores de Tempo
5.
Neurogastroenterol Motil ; 13(2): 155-62, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11298994

RESUMO

The jejunal inflammation induced in rats by the nematode Nippostrongylus brasiliensis is followed by intestinal neuroimmune alterations including mast cell hyperplasia and nerve remodelling. On the other hand, cholecystokinin (CCK) plays a pivotal role in the regulation of intestinal motility. The aim of this study was to determine whether the intestinal motor response to CCK is altered 30 days after infection by N. brasiliensis. Thus, CCK-8 (50 microg kg(-1) intraperitoneally) disrupted the pattern of jejunal migrating myoelectric complexes for a longer time in postinfected rats (95.5 +/- 3.5 min) than in controls (48.1 +/- 5.1 min). This enhanced jejunal response was also found after oral administration of the potent releaser of endogenous CCK, soybean trypsin inhibitor. In contrast, no alteration of the inhibition of colonic motility by CCK administration was observed. The increased responsiveness of jejunal motility to CCK persisted after mast cell stabilisation or depletion but was prevented by atropine, devazepide and L-365260 (CCK-A and CCK-B receptor antagonists, respectively) and vagotomy. These results indicate that neuroimmune alterations after N. brasiliensis infection lead to an increased intestinal motility response to CCK that involves a cholinergic mediation, a vagal pathway and alterations in intestinal CCK-A and CCK-B receptors.


Assuntos
Jejuno/parasitologia , Nippostrongylus , Receptores da Colecistocinina/metabolismo , Sincalida/farmacologia , Infecções por Strongylida/fisiopatologia , Nervo Vago/metabolismo , Animais , Motilidade Gastrointestinal/efeitos dos fármacos , Motilidade Gastrointestinal/fisiologia , Jejuno/inervação , Jejuno/fisiopatologia , Masculino , Mastócitos/metabolismo , Mastócitos/parasitologia , Proteínas de Plantas/farmacologia , Ratos , Ratos Wistar , Receptores da Colecistocinina/antagonistas & inibidores , Receptores Muscarínicos/metabolismo , Inibidores da Tripsina , Nervo Vago/parasitologia , alfa-Amilases/antagonistas & inibidores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA